Olmicard Tablets / Film-coated

Olmesartan Medoxomil
20mg
Nexgen Pharma FZ LLC
Pack size 30's (10's Blister x 3)
Dispensing mode POM
Source UAE
AgentARABIAN ETHICALS CO.
Retail Price 61.50 AED

Available as:

40mg - Tablets / Film-coated

Indications

Olmicard Tablets / Film-coated is used for: Hypertension, Diabetic nephropathy,

Adult Dose

Oral Hypertension Adult: Initial: 10-20 mg once daily may then be increased up to max 40 mg once daily if needed. Elderly: No dosage adjustment needed. Hepatic impairment: Moderate: Initial: 10 mg once daily may increase up to max 20 mg once daily.

Child Dose

Oral Hypertension Child: 6-16 yr <35 kg: 10 mg once daily; dosage range: 10-20 mg/day >35 kg: 20 mg once daily. Doses may be doubled once if necessary after 2 wk. dosage range: 20-40 mg/day

Renal Dose

Renal impairment: Mild to moderate (CrCl: 20-60 mL/min): Max: 20 mg once daily.

Administration

Contra Indications

Pregnancy (2nd and 3rd trimesters); biliary obstruction.

Precautions

Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation. Lactation: No human data; use with caution

Pregnancy-Lactation

Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D

Interactions

Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.

Adverse Effects

Side effects of Olmesartan Medoxomil : 1-10% Dizziness, Headache, Fatigue, Diarrhea, Hyperglycemia, Hypertriglyceridemia, Back pain, Bronchitis, Inflicted injury, Flulike symptoms, Pharyngitis, Rhinitis, Sinusitis, Upper respiratory tract infection (URTI) Frequency Not Defined (selected) Anaphylactic reaction, Angioedema, Facial edema, Rhabdomyolysis, Hyperkalemia, Tachycardia, Hypercholesterolemia, Gastroenteritis, Hyperlipidemia Potentially Fatal: Acute renal failure.

Mechanism of Action

Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.

Note

Olmicard 20mg Tablets / Film-coated manufactured by Nexgen Pharma FZ LLC. Its generic name is Olmesartan Medoxomil. Olmicard is availble in United Arab Emirates. Farmaco UAE drug index information on Olmicard Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Olmesartan Medoxomil :

Tablets / Film-coated
Olmac 20 20mg
Macleods Pharmaceuticals Ltd.
Tablets / Film-coated
Olmac 40 40mg
Macleods Pharmaceuticals Ltd.
Tablets / Film-coated
Olmepress 20mg
Laboratorios Cinfa S.A
Tablets / Film-coated
Olmepress 40mg
Laboratorios Cinfa S.A
Tablets / Film-coated
Olmespec 20mg
Aurobindo Pharma FZ LLC